Milestone Pharmaceuticals Inc

NASDAQ MIST

Data sourced from

and

Daily

Download Data

Milestone Pharmaceuticals Inc Enterprise Value (EV) on June 03, 2024: USD 42.14 M

Milestone Pharmaceuticals Inc Enterprise Value (EV) is USD 42.14 M on June 03, 2024, a -62.47% change year over year. Enterprise Value is a measure of a company's total value, including both its equity and debt. It represents the theoretical takeover price of a company and is often used in valuation methods. Enterprise value is calculated as the sum of a company's market capitalization, total debt, and subtracting its cash and short-term investments.

Milestone Pharmaceuticals Inc 52-week high Enterprise Value (EV) is USD 141.65 B on August 10, 2023, which is 336,038.27% above the current Enterprise Value (EV).
Milestone Pharmaceuticals Inc 52-week low Enterprise Value (EV) is USD -15.61 M on March 14, 2024, which is -137.04% below the current Enterprise Value (EV).
Milestone Pharmaceuticals Inc average Enterprise Value (EV) for the last 52 weeks is USD 1.19 B.

NASDAQ: MIST

Milestone Pharmaceuticals Inc

CEO	Mr. Joseph G. Oliveto M.B.A.
IPO Date	May 9, 2019
Location	Canada
Headquarters	1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
Employees	47
Sector	Healthcare
Industry	Biotechnology

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key trends